North AmericaCACountry Report

Psychedelic Research in

Canada

Canada remains one of the more active psychedelic research jurisdictions outside the United States, but its policy model is cautious and tightly medical-regulatory. Classical psychedelics are controlled substances; psilocybin and MDMA are not generally authorised medicines; and when those compounds are used clinically, they are usually accessed through clinical trials or narrow patient-specific routes such as the Special Access Programme and related CDSA exemptions.

Key Insights

A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Canada.

1
Canada is research-rich and access-poor: the trial and academic pipeline is deeper than the routine care route.
2
Spravato is real Canadian market access; psilocybin and MDMA are still exceptional-access or research substances.
3
Off-label ketamine is materially important in practice, but it is not regulatory approval for psychiatric use.
4
Reimbursement remains a structural bottleneck, with negative or absent public-plan decisions even for authorised esketamine.
5
Toronto is the clearest national hub in the current source set, while Ottawa is unusually important for palliative-care work.
6
The next major shifts are more likely to come from trial read-outs, sponsor filings and payer decisions than broad legislative liberalisation.

Research Snapshot

Blossom currently tracks 91 psychedelic clinical trials connected to Canada, including 35 active studies.

Active trials: 35
Total trials: 91
Stakeholders: 93
Events: 11

Top Compounds

Psilocybin(38)
Ketamine(36)
MDMA(7)
Esketamine(6)

Active Trial Preview

View all trials →

Medical Access Snapshot

Canada has limited medical access rather than general psychedelic medicine approval. Spravato is marketed, racemic ketamine is authorised as an anaesthetic and used off-label in some psychiatric and pain settings, and psilocybin or MDMA access remains exceptional through clinical trials, the Special Access Programme and related CDSA exemptions. Public reimbursement is limited: CDA-AMC recommended that esketamine not be reimbursed, BC PharmaCare treated Spravato as non-benefit, and Ontario/WSIB materials show only narrow formulary handling for ketamine...

View trials→View stakeholders→View events→Open access guide→

Regulatory Status

In Canada, Health Canada regulates medicines under the Food and Drugs Act and Food and Drug Regulations, while the Controlled Drugs and Substances Act governs controlled substances. Ketamine and MDMA are controlled under CDSA Schedule I. LSD, psilocybin, psilocin, mescaline and DMT are controlled under Schedule III. Psilocybin and MDMA are also treated as restricted drugs for federal medicines-control purposes, so access outside authorised research needs specific legal mechanisms. Since January 2022, practitioners have been able to request restricted drugs such as psilocybin and MDMA through the Special Access Programme, but SAP remains case-by-case, for serious or life-threatening conditions where conventional options have failed, are unsuitable or are unavailable. It is not a substitute for clinical trials or a general approval route. British Columbia's simple-possession pilot expired on 31 January 2026 and was not a therapeutic-authorisation framework.

History of Research in Canada

Canada's modern psychedelic story still begins in Saskatchewan. In the 1950s, psychiatrists Humphry Osmond and Abram Hoffer conducted some of the best-known early clinical work with LSD and mescaline at Weyburn Mental Hospital, especially in alcoholism and psychiatric research. Saskatchewan is also central to the history of the word psychedelic: Osmond coined the term in 1957. # #

That early work did not survive the next regulatory era. As international and domestic control tightened and psychopharmacology moved towards more standardised trial and licensing models, psychedelic research contracted sharply. Canada's federal control framework was later consolidated in the CDSA, which remains the core criminal-law structure for these substances. # #

The modern restart arrived gradually rather than through a single reform. High-profile section 56 psilocybin approvals began in 2020 on a case-by-case basis. A larger structural change followed when federal amendments enabled SAP requests for restricted drugs from January 2022, and Health Canada's 2023 notice then clarified the psychedelic-assisted psychotherapy SAP process and the class exemption for some psilocybin and MDMA activities tied to SAP authorisations. # #

Since then, the restart has become more institutional. CIHR announced nearly C$3 million in 2023 for psilocybin-assisted psychotherapy trials, and by 2024 to 2026 the Canadian pipeline included palliative distress, treatment-resistant depression, OCD, chronic neuropathic pain and phase III COMP360 depression work. The publication of PSYCHED-PAL in 2026 added peer-reviewed Canadian palliative-care outcomes, although the design was small and uncontrolled. # # # # #

Toronto-Ottawa Corridor Spotlight

The strongest regional spotlight is Toronto and the wider Greater Toronto academic corridor. The reviewed source set shows activity across compounds, indications and institutions: CAMH in psilocybin and OCD, Unity Health Toronto and St. Michael's in MDMA for chronic neuropathic pain, and Princess Margaret Cancer Centre in intranasal ketamine for advanced cancer and palliative-care depression. # # #

That mix matters because it is not one sponsor or one disease area. Toronto combines hospital pain programmes, academic psychiatry, cancer and palliative care, and translational psychopharmacology. It also hosts Canadian participation in multinational depression development. # # #

Ottawa is the most important secondary node in the reviewed sources, especially for palliative care and end-of-life distress. The Ottawa Hospital Research Institute and Bruyere-linked PSYCHED-PAL work give the city unusual importance for researchers and policy professionals interested in palliative indications and ethically complex access questions. # # #

For ecosystem mapping, Canada should be framed as institution-led rather than clinic-led. Sponsor-owned pages and recruitment materials are useful for study status and site identification, but they should not be treated as independent efficacy evidence. # # #

Research Focus

The dominant visible Canadian research signal is psilocybin. Current registry and institutional sources show work in end-of-life distress, treatment-resistant depression, OCD, alcohol use disorder, chronic neuropathic pain, post-concussion symptoms and multinational depression development. The breadth matters because Canada is testing clinical, population-specific and implementation questions, not only depression efficacy. # # # # #

Palliative and advanced-illness work is one of Canada's most distinctive niches. Ottawa's PSYCHED-PAL programme has a published single-arm study and a recruiting randomised follow-up trial, while Toronto's Princess Margaret Cancer Centre generated intranasal racemic ketamine data in advanced cancer and palliative-care depression. These studies are evidence signals, not general access routes. # # #

MDMA work appears more selective but clinically important. EASEPain is a recruiting phase II trial at St. Michael's Hospital in Toronto for chronic neuropathic pain, comparing MDMA with methylphenidate alongside psychotherapy. That is a useful counterpoint to the more familiar PTSD-centred MDMA narrative. # #

The practical research question for Canada is whether trial strength can translate into funded, repeatable services. Health Canada's SAP route can help individual patients in narrow cases, but it is not designed to replace clinical development, market authorisation or payer assessment. # # #

Key Milestones

1950s

Saskatchewan becomes a major early centre of LSD and mescaline research through Humphry Osmond and Abram Hoffer's work on alcoholism and psychiatry.

1957

Humphry Osmond coins the term psychedelic.

14 May 1997

The Controlled Drugs and Substances Act comes into force, consolidating the federal control framework that still governs psychedelic substances today.

Aug 2020

The first high-profile modern legal psychotherapeutic psilocybin use is approved through a section 56 exemption pathway.

Jan 2022

Food and Drug Regulations amendments make it possible for practitioners to request restricted drugs such as psilocybin and MDMA through the SAP.

27 Feb 2023

Health Canada issues its SAP notice on psychedelic-assisted psychotherapy and confirms a class exemption for some psilocybin and MDMA SAP activities.

29 Jun 2023

CIHR announces nearly C$3 million for three psilocybin-assisted psychotherapy clinical trials.

2023

Canadian phase III COMP360 treatment-resistant depression work receives Health Canada trial clearance and starts.

8 Jan 2024

The Ottawa Hospital Research Institute PSYCHED-PAL phase I/II palliative-distress study starts.

3 Sep 2024

CAMH's psilocybin-assisted psychotherapy trial for treatment-resistant OCD starts.

30 Jan 2026

PSYCHED-PAL publishes early Canadian palliative-care outcomes in Palliative Medicine.

31 Jan 2026

British Columbia's simple-possession pilot expires and is not renewed.

13 Feb 2026

EASEPain is listed as recruiting, phase II, for chronic neuropathic pain.

Future Outlook

Over the next 12 to 24 months, the most plausible Canadian change is better evidence rather than broad legal liberalisation. Canada already hosts studies that could shape practice discussions, including phase III COMP360 work, Ottawa palliative trials, Toronto pain research and CAMH-led psilocybin protocols. The likely output is a mix of feasibility data, mechanistic findings and site-level experience. # # # #

Regulatory authorisation is separate from evidence generation. Health Canada's SAP position says exceptional access is not a substitute for approval, and the reimbursement route remains conservative. Even if a future sponsor submission succeeds for a classical psychedelic indication, Canadian access would still depend on health technology assessment and provincial listing decisions. # # # #

The main uncertainty is where uptake would concentrate first if evidence strengthens. The likely early beneficiaries are established hospital-linked and academic centres already running these protocols, not a broad retail-clinic market. Canada may therefore remain a country where research participation and specialist referral matter more than consumer-facing access narratives. # # #